What is she best known for?
The fields of study she is best known for:
- Gene
- Cancer
- Internal medicine
Julie Teruya-Feldstein mostly deals with Cancer research, Cell biology, Tumor suppressor gene, Carcinogenesis and Lymphoma.
Her Cancer research research incorporates themes from Ubiquitin, Immunology, microRNA, Tumor progression and In vivo.
Her Cell biology research integrates issues from Cancer cell, Molecular biology, Transcription factor and Genetics.
Her study in Tumor suppressor gene is interdisciplinary in nature, drawing from both Cell cycle, RHEB, Neovascularization and RPTOR.
The Carcinogenesis study combines topics in areas such as Cell aging, B cell, B-cell lymphoma, Phosphorylation and Proto-Oncogene Proteins c-myc.
Her Lymphoma study is related to the wider topic of Pathology.
Her most cited work include:
- Tumour invasion and metastasis initiated by microRNA-10b in breast cancer (2111 citations)
- Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer (1151 citations)
- miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis (1057 citations)
What are the main themes of her work throughout her whole career to date?
Her main research concerns Cancer research, Pathology, Lymphoma, Internal medicine and Immunology.
Her work investigates the relationship between Cancer research and topics such as Carcinogenesis that intersect with problems in Cell biology.
Her study brings together the fields of Immunophenotyping and Pathology.
In Lymphoma, Julie Teruya-Feldstein works on issues like B cell, which are connected to Molecular biology.
Her work carried out in the field of Internal medicine brings together such families of science as Gastroenterology, Surgery and Oncology.
Her work in Immunology addresses subjects such as Haematopoiesis, which are connected to disciplines such as Myeloid leukemia, Bone marrow and Cellular differentiation.
She most often published in these fields:
- Cancer research (34.80%)
- Pathology (28.94%)
- Lymphoma (28.21%)
What were the highlights of her more recent work (between 2015-2021)?
- Cancer research (34.80%)
- Lymphoma (28.21%)
- Pathology (28.94%)
In recent papers she was focusing on the following fields of study:
Her primary areas of study are Cancer research, Lymphoma, Pathology, Internal medicine and Cell biology.
Julie Teruya-Feldstein has included themes like Myeloproliferative neoplasm, Cell growth, Progenitor cell, Regulation of gene expression and PTEN in her Cancer research study.
Her studies deal with areas such as Tumor microenvironment, HMGA1, Germinal center and Synthetic lethality as well as Lymphoma.
Her Internal medicine study integrates concerns from other disciplines, such as Orthopedic surgery and Oncology.
Her research in Cell biology intersects with topics in Myeloid, Cellular differentiation and Lethality.
The various areas that Julie Teruya-Feldstein examines in her Haematopoiesis study include Myeloid leukemia and Immunology.
Between 2015 and 2021, her most popular works were:
- Self-renewal of a purified Tie2+ hematopoietic stem cell population relies on mitochondrial clearance. (143 citations)
- Loss of the HVEM tumor suppressor in lymphoma and restoration by modified CAR-T cells (118 citations)
- Reactivation of PTEN tumor suppressor for cancer treatment through inhibition of a MYC-WWP1 inhibitory pathway (106 citations)
In her most recent research, the most cited papers focused on:
- Gene
- Cancer
- Internal medicine
Julie Teruya-Feldstein mostly deals with Cancer research, Myeloid leukemia, Haematopoiesis, PTEN and Cancer.
Her biological study spans a wide range of topics, including Ubiquitin, Progenitor cell, Suppressor, Carcinogenesis and Phosphatase.
Her study with Haematopoiesis involves better knowledge in Cell biology.
Her work deals with themes such as Cell growth, Sterol regulatory element-binding protein, Metastasis, Prostate cancer and MAPK/ERK pathway, which intersect with PTEN.
The study incorporates disciplines such as Myelodysplastic syndromes and Pathology in addition to Stem cell.
Her Human leukocyte antigen study combines topics from a wide range of disciplines, such as Internal medicine and Lymphoma.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
